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Abstract 
Background: The larval stage of the tapeworm Echinococcus granulosus is the causative agent of hydatid disease in 
humans. This zoonotic parasitic infection remains a major health problem in certain areas of the world where is still 
endemic. In view of the ineffectiveness of some drug treatments, the surgical removal of cysts remains the preferred 
treatment option together with the administration of albendazole and mebendazole. However, severe side effects of 
these drugs have been reported which demands developing new scolicidal agents that confer suitable efficacy and 
fewer side effects during surgery.
Methods: To that purpose, in the present work we assessed the effectiveness of ivermectin (IVM), a macrocyclic 
lactone endectocide that has shown to be an effective nematocidal drug against other important parasitic infections. 
To overcome the limitations observed in some drug formulations and resistance, we used nano lipid carriers (NLCs) 
as a targeted and sustained drug delivery system for IVM. We evaluated the in vitro cestocidal and apoptotic effects of 
NLCs‑loaded IVM versus IVM by quantifying the expression of caspase‑3 mRNA.
Results: We found that after 60 and 120 min of administration, 800 μg/ml and 400 μg/ml NLCs‑loaded IVM induced 
100% mortality, respectively. On the other hand, the 800 μg/ml of IVM induced 100% mortality rate 150 min after 
administration. Additionally, we found that NLCs‑loaded IVM induced higher mRNA caspase‑3 expression suggesting 
a more potent apoptotic effect on the parasite.
Conclusions: These data suggest that NLCs‑loaded IVM may be a promising alternative to current treatments 
although in vivo studies are needed.
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Background
Cystic hydatid disease (CHD), known as hydatidosis, 
is an important zoonosis both in humans and animals 
worldwide. The helminth Echinococcus granulosus is the 
causative agent whose definitive hosts are canids, such as 
dogs and foxes. The intermediate hosts (herbivorous or 
omnivorous mammals such as humans, domestic animals 
and wildlife species) can become infected with contami-
nated food, water or by direct contact with infected dogs 
[1, 2]. Africa, Europe, Asia, Central and South America 
are the endemic areas for CHD [3, 4]. Hydatid disease 
causes adverse and slowly developing cysts, which occur 
in the liver, lungs, spleen, brain, bone marrow, and rarely 
in other organs, and are often asymptomatic [1, 4, 5].
To date, the preferred treatment and definitive therapy 
for hydatid cysts is a surgical procedure. However, due to 
multiple lesions in various organs or the development of 
cysts in high risk organs, surgery is not always applica-
ble. Furthermore, the results of surgical procedures have 
not always been successful and in some cases have been 
accompanied by anaphylactic shock, asthma and recur-
rence of the disease [6, 7]. Currently, chemotherapy and 
percutaneous aspiration, injection of chemicals and re-
aspiration (PAIR) are alternative treatments for CHD 
[8]. Many efforts have been made to provide an effective 
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drug for cystic hydatidosis. Up to now, different scoli-
cidal compounds have been used in order to deactivate 
the contents of the cysts, but have been accompanied by 
adverse side effects, such as sclerosing cholangitis, necro-
sis of the liver and methaemoglobinaemia [6–8].
Two benzimidazoles, albendazole and mebendazole, 
are drug therapies routinely used for CHD before and 
after the surgery [9]; however, several side effects of these 
drugs have been reported such as thrombocytopenia, 
leucopenia, alopecia, embryotoxic and hepatotoxicity 
[10]. Hence, developing new scolicidal agents that confer 
suitable efficacy and fewer side effects is necessary to be 
used during surgery [6, 7]. Ivermectin (IVM), as a mac-
rocyclic lactone endectocide, is an agonist of neurotrans-
mitter and binds to gamma-aminobutyric acid (GABA) 
receptor. Abrogation of the nerve impulses culminates 
in paralysis and death of the parasite [11–13]. Nano 
lipid carriers (NLCs) are a delivery system composed of 
a solid matrix that contains liquid nano-fatty particles. 
These nanoparticles are approved by the Food and Drug 
Administration (FDA) and European Medicines Agency 
(EMA) and possess a controlled and continuous release 
capability, have a cellular dimension and are compatible 
with tissues and cells [14]. These nano lipid carriers pro-
duce nano-capsules containing the drug with higher per-
meability and concentrations and, there upon, resolves 
concerns such as side effects, low drug solubility in water 
and lack of adequate drug delivery to protoscoleces 
(PSCs) in cysts. In the present study, NLCs-loaded IVM 
were used against PSCs. The expression of caspase-3, 
which is one of the unknown pathways of immunity in 
the parasite, was studied in the PSCs.
Methods
Preparation of NLCs‑loaded IVM
DL-lactide and glycolide were purchased from Sigma-
Aldrich (St. Louis, MO, USA) and recrystallized with 
ethyl acetate. Stannous octoate (Sn(Oct) 2:stannous 
2-ethylhexanoate), nano lipid carriers (molecular weight 
of 2000, 3000 and 4000), dimethyl sulfoxide, polyethylene 
glycol (PEGs) and poloxamer 407 were purchased from 
Sigma-Aldrich. Glyceryl palmitostearate (Precirol® ATO 
5) was purchased from Gattefossé (Lyon, France). The 
NLCs-loaded IVM were prepared using the hot homog-
enization technique [15]. In this method, the IVMs was 
dissolved in ethanol and added to molten lipidic phase 
(precirol + myglyol) and mixed completely. Then, the 
aqueous phase containing the emulsifier was added drop-
wise to the lipidic phase at the same temperature under 
homogenization at 20,000× rpm for 20 min. The NLCs 
nanoparticles were then produced by solidifying the hot 
nanoemulsion by cooling down to room temperature.
Characterization of nanoparticles
To assess the possible interaction between the drug and 
carrier, Fourier transform infrared (FTIR) spectroscopy 
was used. Lyophilized empty NLCs and drug-loaded 
NLCs were embedded in KBr pellets and FTIR spectra 
of samples were recorded using a FTIR spectropho-
tometer (Shimadzu, Kyoto, Japan). The scans were per-
formed over a wave number range of 4000–400  cm−1. 
Particle size, polydispersity index (PDI) and zeta poten-
tial of synthesized nanoparticles were measured by 
dynamic light scattering (DLS) (Zetasizer-ZS, Malvern, 
UK). The surface morphology of the nanospheres dur-
ing the incubation period was evaluated by scanning 
electron microscopy (SEM) (Phenom ProX, Phenom-
World B.V., Eindhoven, Netherlands).
PSC collection, culturing, and genotyping
Hydatid cysts of E. granulosus were collected from 
the livers of naturally infected sheep (East Azerbaijan, 
Northwest Iran). The hydatid fluid was aspirated and 
transferred into a test tube under sterilized conditions. 
The PSCs were centrifuged at 800× rpm for 5 min. The 
live PSCs were cultured in hydatid fluid treated con-
taining 100 IU/ml penicillin and 100 μg/ml streptomy-
cin, and were subsequently incubated at 37 °C [16, 17]. 
To determine the E. granulosus genotype, DNA extrac-
tion was performed with a commercial kit (DNG-plus™ 
solution; CinnaGen, Tehran, Iran) according to the 
manufacturer’s instructions. Polymerase chain reac-
tion (PCR) was conducted to amplify the cytochrome 
c oxidase subunit 1 gene (cox1) in a volume of 20 μl, 
containing Taq DNA polymerase (1 U), deoxynucleo-
tide triphosphate (dNTP, 250 μM), Tris-HCl (pH 9.0, 
10 mM), KCl (30 mM),  MgCl2 (1.5 mM), template DNA 
(50 ng) and 1 μl of each primer (10 pmol). Details of the 
primer sequences used for PCR were described previ-
ously [17, 18]. To identify the PSC genotype, the ampli-
cons were directly sequenced (Pouya Gostar Gene, 
Tehran, Iran).
Scolicidal assay
In the present study, various scolicidal concentrations of 
IVMs and NLCs-loaded IVM (50, 100, 200, 400 and 800 
μg/ml) were tested at different exposure times (15, 30, 60, 
120 and 150 min). To assess the viability of PSCs, 10 μl 
of 0.1% eosin dye was added to the 20 μl remaining pel-
let of PSC and mixed gently. Dead PSCs absorbed eosin, 
but live PSCs remained colorless. The percentages of 
dead PSCs were estimated by counting a minimum of 300 
PSCs. In this study, phosphate buffered saline (PBS) and 
NLCs were used as negative controls [16].
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DNA fragmentation assay
DNA fragmentation occurring during apoptosis was 
analyzed by agarose gel electrophoresis. Briefly,  104 
PSCs treated with IVMs and NLCs-loaded IVM were 
exposed for 24 h. Then, the DNA extraction was per-
formed by the DNGplus™ solution (CinnaGen, City, 
Iran). Finally, gel electrophoresis was performed using 
4 μl of the DNA extract on a 1.5% agarose gel, stained 
and observed under UV light.
Scanning electron microscopy
The treated PSCs were washed three times in PBS. 
Afterwards, PSCs were fixed in 3% glutaraldehyde for 
12 h at room temperature. Following fixation, dehy-
dration of the PSC was carried out in ascending con-
centrations of ethanol. Finally, processed samples were 
sputter-coated with gold and examined by SEM (Phe-
nom ProX) [17].
Isolation of total RNA and synthesis of complementary 
DNA (cDNA)
The total cellular RNA was isolated from the untreated 
and treated PSCs following 15 h of exposure time 
using an RNX Plus Kit (CinnaGen). The quality and 
quantity of isolated RNA were evaluated by a Nan-
oDrop 2000c spectrophotometer (Thermo Fisher Sci-
entific, Waltham, MA, USA). Subsequently, the RNA 
was reverse-transcribed into cDNA and used as the 
template for PCR amplification using a reverse tran-
scriptase kit (Thermo Fisher Scientific).
Primer designing and quantitative real‑time polymerase 
chain reaction (qRT‑PCR)
In order to evaluate the apoptotic effects of IVMs and 
NLCs-loaded IVM on the cultured PSC, the specific 
primers of E. granulosus caspase-3 gene were designed 
by the Oligo Analyzer v.3.1 tool based on reference 
accession numbers of AB306934 (EF-1α) and LK028577 
(caspase-3). Primer sequences and cycling conditions 
have already been described [17]. Real-time PCR was 
performed to determine the level of caspase-3 messen-
ger RNA (mRNA) expression. The real-time PCR was 
carried out in a 20 μl reaction volume, containing 1 μl 
of cDNA (50 ng), 1.5 mM of  MgCl2, 125 μM of dNTP, 
0.1 U/µl Taq DNA Polymerase, and 0.5 pmol of specific 
primers.
Statistical analysis
GraphPad PRISM v.5 (GraphPad Software, La Jolla, 
CA, USA; http://www.graph pad.com) was used to 
draw graphs and conduct the statistical analysis. The 
normality of scale variables was evaluated by the 
Kolmogorov–Smirnov test. Differences between the 
test and control groups for nominal variables were ana-
lyzed using the Mann–Whitney U-test and one-way 
analysis of variance (ANOVA). A P-value < 0.05 was 
considered as statistically significant and data were rep-
resented as the mean ± standard error of the mean.
Results
Genotyping of E. granulosus PSCs
To determine the genotype of the E. granulosus PSCs, 
PCR amplification by targeting the cytochrome c oxidase 
subunit 1 gene (cox1) was performed. Based on sequenc-
ing analysis, the G1 genotype (sheep strain) was con-
firmed (Additional file 1: Figure S1).
SEM micrograph and zeta potential
The SEM micrograph of IVM-loaded NLC shown in 
Fig.  1a indicates that the polymeric nanoparticles were 
well distributed in the solution. In addition, the zeta 
potential distribution is also shown in Fig. 1b.
Scolicidal effects of IVMs and NLCs‑loaded IVM
The scolicidal effects of various concentrations of IVMs 
and NLCs-loaded IVM (50, 100, 200, 400 and 800 μg/
ml) were tested at different exposure times (15, 30, 60, 
120 and 150 min) (Additional file  2: Figure S2). Statis-
tically significant differences were observed between 
800 μg/ml IVMs at exposure times of 120 and 150 min 
(mortality rates of 96% and 100%, respectively) and the 
other concentrations and control group (PBS) (ANOVA: 
F(1.2, 6) = 10.24, P = 0.0164; Fig.  2). However, the 50 μg/
ml IVMs had an increasing scolicidal effect between 
15 min (mortality rate of 20%) and 150 min (mortality 
rate 80%; Fig.  2). Remarkably, 800, 400 and 200 μg/ml 
of NLCs-loaded IVM could reach 100% mortality in 60, 
120 and 150 min, respectively. These results were statisti-
cally significant compared with the other concentrations 
and control group (ANOVA: F(1.1, 5.6) = 16.69, P = 0.0065; 
Fig. 3). The 50 μg/ml IVMs-loaded NLC was able to yield 
an increasing scolicidal effect between 15 min (mortality 
rate of 35%) and 150 min (mortality rate of 96%) of expo-
sure (Fig.  3). The ultrastructural morphology of PSCs 
treated by NLCs-loaded IVM is shown in Fig. 4.
Evaluation of caspase‑3 mRNA expression and DNA 
fragmentation
In this study, apoptosis was assessed by caspase-3 mRNA 
expression and DNA fragmentation assay. The expression 
of caspase-3 mRNA was assessed by the qRT-PCR after 
15 h exposure (Fig. 5). Caspase-3 mRNA expression was 
higher in both PSC treated with IVMs and PSC treated 
with NLCs-loaded IVM relative to the control groups 
(PBS, Mann–Whitney U-test: Z  = − 2.80224, P = 0.005; 
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Fig. 1 a SEM micrograph of NLCs‑loaded IVM. b Zeta potential determination of NLCs‑loaded IVM nanoparticles
Fig. 2 Scolicidal effects of IVMs against PSCs of E. granulosus at 
different concentrations following various exposure times (ANOVA: 
F(1.2, 6) = 10.24, P = 0.0164)
Fig. 3 Scolicidal effects of NLCs‑loaded IVM against PSCs of E. 
granulosus at the different concentrations following various exposure 
times (ANOVA: F(1.1, 5.6) = 16.69, P = 0.0065)
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and NLCs, Mann–Whitney U-test: Z = − 2.50672, 
P = 0.01); however, the apoptosis rate was significantly 
different (Mann–Whitney U-test: Z = − 2.64, P = 0.015) 
between the PSCs treated with IVMs and IVM-loaded 
NLCs.
Discussion
In the present study, aiming to find an alternative effi-
cient treatment, we evaluated the in vitro cestocidal 
and apoptotic effects of NLCs-loaded IVM based on the 
nematocidal effectiveness of this compound. Treatment 
and management options for CHD include surgery, per-
cutaneous treatment, antiparasitic drug treatment and 
monitoring [19]. Among them, surgery is the preferred 
approach; however, some unpredicted outcomes of sur-
gery, such as anaphylactic shock, recurrence of disease 
and locating cysts in risky tissues, have made the appli-
cation of alternative options necessary (such as chemo-
therapy) [20]. To date, benzimidazoles derivatives, such 
as mebendazole and albendazole, are recommended 
chemotherapy drugs [9]. However, due to side effects 
and the poor water-solubility of benzimidazoles, a new 
Fig. 4 Ultrastructural morphology of treated PSC after 30 min using scanning electron microscopy (SEM). Protoscolices of E. granulosus treated 
with PBS (a), 50 μg/ml IVMs (b), 50 μg/ml NLCs‑loaded IVM (c), and a zoomed image of a damaged protoscolex (d) (a, b invaginated protoscolces; c 
evaginated protoscolex)
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therapy is needed; the ideal therapy for CHD should pro-
vide maximum treatment efficiency and minimize the 
adverse side effects [21, 22]. In addition, other antipara-
sitic drugs, such as praziquantel and nitazoxanide, occa-
sionally have also been used against hydatic cysts in 
animals and humans [23, 24]. IVM, commercially avail-
able as oral suspensions for small ruminants, dogs and 
humans, has been reported to be effective against human 
strongyloidiasis, filariasis, cutaneous larva migrans and 
intestinal nematodes including Ascaris lumbricoides, 
Trichuris trichiura and Enterobius vermicularis [13, 25]. 
The activity route of IVM is related to glutamate-gated 
chloride channels. Upon binding, IVM paralyzes the 
body-wall muscles and more-potent effects occur on 
the pharyngeal musculature [26]. Besides nematocidal 
activity, in vitro cestocidal effects of IVM have also been 
reported [27]. Campbell et al. [28] reported that IVM had 
no effects on cestodes whereas Casado et al. [29] found 
a significant in vitro effect on the hydatid cyst PSCs. 
Although using a different approach, our results con-
firmed in vitro protoscolicidal effect of IVM. The differ-
ences in evaluation approaches in other studies might 
be the cause of conflicting results. In this regard, after in 
vitro incubation of E. granulosus PSCs with IVM, Mar-
tínez et  al. [30] suggested some changes in expression 
level of heat-shock proteins (HSP) (decreased hsp70 and 
increased hsp60 levels). Furthermore, Pérez-Serrano 
et  al. [31] proposed a tegumental depolarization of the 
PSCs incubated in vitro with IVM that can be essential 
for parasite survival. However, some limitations observed 
in the strategy of formulations and drug resistances have 
encouraged the researchers to improve formulation lies 
in the state-of-the-art delivery systems. Recently, some 
studies have shown that nanomedicines offer new insight 
into the development of existing management strategies 
and can enhance both the solubility and stability of drugs 
[14, 32]. NLCs are a new generation of lipid nanoparticles 
that have been developed through the combination of 
advantages from different nanocarriers. This kind of car-
rier seems to be a suitable delivery system intended for 
topical, oral, pulmonary, ocular and parenteral admin-
istration of drugs [33–35]. We based our study on the 
successful effect of IVM against PSCs from previous 
studies. For example, Casado et  al. [36] showed a more 
rapid scolicidal effect of IVM, so that no cyst develop-
ment was observed in mice inoculated with PSCs (100 µg 
for 72 h). Furthermore, the study showed that after 16 h 
of exposure to 100 µg of IVM, a rostellar disorganization 
occurred and a complete paralysis of PSCs was observed 
after 48 h. Ochiengʼ-Mitula et al. [37] investigated IVM 
during per-cutaneous drainage of E. granulosus hydatid 
cysts. Results of this study showed that injection of IVM 
Fig. 5 a An expression of caspase‑3 mRNA level in PSCs treated with PBS (negative control), PSCs treated with NLCs (negative control), PSCs treated 
with IVMs, and PSCs treated with NLCs‑loaded IVM. Bar graph indicates the mean ± standard deviation. Caspase‑3 mRNA expression was higher 
in both PSC treated with IVMs and NLCs‑loaded IVM than the control groups (PBS, Mann–Whitney U‑test: Z = − 2.80224, P = 0.005; NLCs, Mann–
Whitney U‑test: Z  = − 2.50672, P = 0.01). b Protoscolex DNA fragmentation after treatment with IVMs (Lane 1), PBS (Lane 2), NLCs‑loaded IVM (Lane 
3), NLCs (Lane 4) and a 100‑bp DNA marker (Lane M)
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into a cystic hydatid caused cyst collapse and death of 
PSCs with ultrastructural changes on the germinal layer. 
Thus, based on the probed advantages of NLCs and 
the effectiveness of IVM, NLCs-loaded IVM were syn-
thetized to overcome cyst wall barriers. The results of 
the present study were significant: NLCs-loaded IVM 
showed more efficient activity in comparison to IVMs, 
causing up to 100% mortality. Similar studies have used 
nanoparticle derivations as a novel and alternative treat-
ment approach. Moazeni et  al. [38] studied the in vitro 
and in vitro antihydatid activity of a nano emulsion of 
Zataria multiflora, a native flowering plant from south-
western Asia, observing an 88–100% scolocidal effect 
after 20 minutes of exposure. Rahimi et  al. [16] showed 
a high scolicidal effect of biogenic Ag-NPs, in which the 
0.15 mg/ml concentration caused a 90% mortality rate 
after 120 minutes of exposure [16]. In the other similar 
in vitro study of fungal chitosan isolated from Penicillium 
spp., 100% mortality was observed after incubating with 
400 µg/ml for 180 minutes [39]. Fungal chitosan seems to 
have stronger scolicidal effects due to beneficial charac-
teristics, such as easy access, low-cost culture, nutrient 
and processing; however, further in vivo and experimen-
tal studies are still needed to attain precise results [40]. In 
vitro and ex vivo activity of Melaleuca alternifolia oil (tea 
tree oil, TTO) at 20 mg/ml indicated 90% protoscolicidal 
action in E. ortleppi hydatid cysts at five minutes [41]. 
Mahmoudvand et al. [42] showed that Zataria multiflora 
Boiss essential oil caused a significant scolicidal effect 
(100%) at the concentrations of 12.5 and 6.25 μl/ml after 
5 and 20 minutes of exposure, respectively [42].
There are two types of hydatid cysts in the intermediate 
hosts, namely fertile and infertile cysts. One of the ways 
to cause infertilization of the cysts is through induction 
of an apoptotic cascade by the host. Fertile hydatid cysts, 
due to the presence of PSCs and antigens 5, B, cyclophilin 
and Δ/β1 prolongation factor, play an important role in 
the development of anaphylactic reactions of hydatid cyst 
during surgery [43, 44]. Therefore, it seems necessary to 
design approaches to induce cyst infertility in vivo.
The innate immunity of humans against the hydatid 
cyst fluid and the hydatid cyst layers, especially the ger-
minal layer, is one of the possible mechanisms for sup-
pressing hydatid cysts as well as the infertility of fertilized 
cysts [45–47]. The new pathways of innate immunity of 
host against hydatid cysts include inflammasome, toll-
like receptor (TLR) and apoptosis. Apoptosis has recently 
been established to be a major component of the host’s 
innate immunity in suppressing parasites [45, 48]. Apop-
tosis is programmed cell death carried out by a series of 
biochemical and morphological events, such as chroma-
tin compression, DNA fragmentation and expression of 
intracellular and extracellular apoptotic molecules [48]. It 
is characterized primarily by DNA fragmentation, forma-
tion of apoptotic bodies and cysteine aspartate-specific 
protease activation. Apoptosis mainly occurs through 
two pathways, an extrinsic pathway belonging to the 
death receptor and the intrinsic pathway through mito-
chondria. These two apoptotic pathways come together 
in a same terminal termed execution pathway, which is 
initiated by activation of caspase-3 and finished by cell 
death [45, 48]. The central components of this machin-
ery are caspases proteins. Caspase-1 and caspase-3 are 
the two cysteine-aspartic acid proteases that play central 
roles in the execution-phase of apoptosis [48, 49]. Stud-
ies have reported a relation between the drug-induced 
apoptosis rate and high level of caspase-1 and caspase-3 
expression in PSCs from E. granulosus [17, 49].
Conclusions
In the present study, a significant difference was observed 
in the scolicidal effects and apoptosis rate between PSCs 
treated with IVMs and PSCs treated with IVM-loaded 
NLCs. In vivo studies of NLCs-loaded IVM and further 
similar studies are still required to develop more effective 
IVM nano-compounds and provide a deep understand-
ing of reactions between NLCs-loaded IVM and PSCs.
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